期刊文献+

TS及EGFR在非小细胞肺癌中表达及其临床意义 被引量:1

Expressions and clinical significance of TS and EGFR in non-small cell lung cancer
原文传递
导出
摘要 目的研究非小细胞肺癌(NSCLC)组织中胸苷酸合成酶(TS)及表皮生长因子受体(EGFR)蛋白的表达及其临床意义。方法免疫组化方法检测431例NSCLC组织中TS及EGFR蛋白表达,评估其与临床病理参数的关系。结果 TS蛋白在NSCLC组织中阳性表达率为35.1%(134/382);其表达水平与肿瘤分化程度及淋巴结转移有关(P<0.05)。EGFR蛋白在NSCLC组织中阳性表达率为74.1%(312/421);其表达水平与病理类型、分化程度及淋巴结转移情况有关(P<0.05)。结论 TS及EGFR蛋白表达与部分临床病理参数相关,对NSCLC诊断及预后的判断可能具有重要价值。 Objective To investigate the protein expressions and clinical significance of thymidylate synthase(TS) and epidermal growth factor receptor(EGFR) in human non-small cell lung cancer (NSCI.C). Methods The protein expressions of TS and EGFR were detected by immunohistochemistry in 431 cases with NSCLC. The relationship between the expressions and clinicopathological characteristics was analyzed. Results The positive expression rates of TS and EGFR in NSCLC were 35.1% (134/382) and 74. 1 % (312/421), respectively. TS expression was correlated with tumor differentiation and lymph node metastasis(P〈0. 05), while EGFR expression was correlated with pathological type, tumor differentiation and lymph node metastasis ( P〈0. 05 ). Conclusion TS and EGFR expressions are associated with part of clinicopathological characteristics, which may play an important role in the diagnosis and prediction of the prognosis of NSCLC patients.
出处 《江苏医药》 CAS 北大核心 2014年第11期1289-1291,共3页 Jiangsu Medical Journal
关键词 非小细胞肺癌 胸苷酸合成酶 表皮生长因子受体 Non-small cell lung cancer Thymidylate synthase Epidermal growth factor receptor
  • 相关文献

参考文献7

  • 1Wang X, Wang Y, Wang Y, et al. Association of thymidylate . synthase gene 3 -untranslated region polymorphlsm with sensi- tivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC [J]. J Biomed Sci,2013,20:5.
  • 2Kaira K, Ohde Y, Nakagawa K, et al. Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma[-J 1. Med Oncol, 2012,29 ( 3 ) : 1663- 1672.
  • 3Yi YW, Hong W, Kang H J, et al. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells[J]. J Cell Mol Med,2013,17 (5):648 -656.
  • 4Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carbo- platin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009,351 (10) :. 947-957.
  • 5Rosell R, Perez-Roca L, Sanchez J J, et al. Customized treatment in non-small-ceil lung cancer based on EGFR mutations and BRCA1 mRNA expression[J]. PLoS One, 2009,4(5) : e5133.
  • 6Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010,11 (2) : 121-128.
  • 7Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival : a meta-analysis[J]. J Natl Cancer Inst, 2013,105 (9): 595-605.

同被引文献6

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部